Abiopharma

🔍 Donovan Joanne M. (Executive)

Company: Edgewise Therapeutics, Inc. (EWTX)

Report Date: 2026-08-12

Detailed Transactions and Holdings:

• Acquired 5,781 shares of Common Stock (Direct)
  Date: 2026-08-12 | Code: M | equity_swap_involved: false | shares_owned_after: 11,035.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 7,031 shares of Common Stock (Direct)
  Date: 2026-08-12 | Code: M | equity_swap_involved: false | shares_owned_after: 18,066.00 | transaction_form_type: 4
• Sold 2,839 shares of Common Stock at $43.784 per share (Direct)
  Date: 2026-08-12 | Code: S | equity_swap_involved: false | shares_owned_after: 15,227.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 2,779 shares of Common Stock at $43.7073 per share (Direct)
  Date: 2026-08-12 | Code: S | equity_swap_involved: false | shares_owned_after: 12,448.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 104 shares of Common Stock at $44.4253 per share (Direct)
  Date: 2026-08-12 | Code: S | equity_swap_involved: false | shares_owned_after: 12,344.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Sold 800 shares of Common Stock at $44.5175 per share (Direct)
  Date: 2026-08-12 | Code: S | equity_swap_involved: false | shares_owned_after: 11,544.00 | transaction_form_type: 4 | Footnotes: F2, F6
• Sold 2,919 shares of Common Stock at $43.4065 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: false | shares_owned_after: 8,625.00 | transaction_form_type: 4 | Footnotes: F7, F8
• Sold 5,781 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-12 | Code: M | Expires: 2034-08-12 | equity_swap_involved: false | shares_owned_after: 11,563.00 | transaction_form_type: 4 | Footnotes: F9
• Sold 7,031 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-12 | Code: M | Expires: 2035-08-12 | equity_swap_involved: false | shares_owned_after: 21,094.00 | transaction_form_type: 4 | Footnotes: F10
• Acquired 32,500 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-12 | Code: A | Expires: 2036-08-12 | equity_swap_involved: false | shares_owned_after: 32,500.00 | transaction_form_type: 4 | Footnotes: F11
• Acquired 65,000 shares of Stock Option (Right to Buy) (Derivative)
  Date: 2026-08-12 | Code: A | Expires: 2036-08-12 | equity_swap_involved: false | shares_owned_after: 65,000.00 | transaction_form_type: 4 | Footnotes: F12

Footnotes:

• F1: Includes 887 shares purchased on May 15, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
• F10: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
• F11: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
• F12: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
• F2: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.
• F3: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.23 to $44.20, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.21, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.42 to $44.43, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.43 to $44.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F7: The sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.
• F8: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.12 to $43.75, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F9: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.